Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01203111
Other study ID # LANTU_R_05048
Secondary ID U1111-1116-3517
Status Completed
Phase Phase 4
First received September 14, 2010
Last updated August 29, 2012
Start date December 2010
Est. completion date July 2012

Study information

Verified date August 2012
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Mexico: Ethics Committee
Study type Interventional

Clinical Trial Summary

Primary Objective:

To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).

Secondary Objectives:

1. Percentage of patients with HbA1c < 7% at week 24.

2. Percentage of patients with HbA1c < 7% and no symptomatic nocturnal hypoglycemia event at week 24.

3. Fasting Plasma Glucose (FPG) and 7-point Self Monitoring of Blood Glucose (SMBG) at week 0, week 12 and week 24.

4. Doses of insulin glargine and insulin glulisine: the daily dose (U) and the daily dose / kg (U/kg) will be calculated at week 24.

5. Systolic and diastolic blood pressure, heart rate, weight change will be measured at week 0, week 12 and week 24.

6. Number of patients suffering hypoglycemias (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe) will be evaluated during the treatment period. 7-Adverse events.


Description:

The study is divided in 3 periods:

1. a 2-week run-in period,

2. a 12-week treatment period 1

3. a 12-week treatment period 2 study treatment duration per patient: 24 weeks study duration per patient: 26 weeks


Recruitment information / eligibility

Status Completed
Enrollment 207
Est. completion date July 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion criteria:

- in the run-in period:

1. Uncontrolled Type 2 diabetes mellitus defined as HbA1c level between 7,5% and 10% assessed over the past 6 months

2. Male or female patients from 18-75 years old inclusive

3. Body Mass Index (BMI) between 25 and 40 kg/m2

4. Currently treated with a basal insulin (NPH, insulin zinc or insulin detemir), plus at least 1g metformin daily, and other Oral Glucose Lowering Drug (OGLD) if any for at least 3 months

5. Signed Informed consent obtained prior to any study procedures

- in the treatment period:

1. HbA1c level between 7,5% and 10% assessed between week -2 and week 0

2. Serum creatinine <= 135 µmol/L in men and <= 110 µmol/L in women

3. Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) <= 3 times the upper limit of normal

4. Negative pregnancy test for women of childbearing potential

Exclusion criteria:

1. Type 1 diabetes mellitus

2. Active proliferative diabetic retinopathy, defined as the application of photocoagulation or surgery performed within 6 months before study entry or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus performed over the past 2 years)

3. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult

4. History of impaired hepatic function defined as Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal

5. History of impaired renal function defined as serum creatinine >135 µmol/l in men and > 110 µmol/l in women

6. History of drug or alcohol abuse

7. Type 2 Diabetes Mellitus (T2DM) patients treated exclusively with OGLDs

8. T2DM patients treated with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)

9. Previous treatment with insulin glulisine

10. Concomitant treatment with thiazolidinediones, exenatide or pramlintide

11. Treatment with systemic corticosteroids within 3 months prior to study entry

12. Treatment with any investigational product within 2 months prior to study entry

13. History of hypersensitivity to the study drugs or to drugs with a similar chemical structure

14. Presence of mental condition that, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the patient

15. Presence of geographic or social conditions that would restrict or limit the patient participation for the duration of the study

16. Pregnant or breast feeding women

17. Women of childbearing potential not protected by effective contraceptive method of birth control

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
INSULIN GLARGINE
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
INSULIN GLULISINE
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal

Locations

Country Name City State
Algeria Administrative office Algiers
Brazil Administrative office Sao Paulo
Israel Administrative office Natanya
Lebanon Administrative office Beirut
Mexico Administrative office Col. Coyoacan
Morocco Administrative office Casablanca
Peru Administrative office Lima
Saudi Arabia Administrative office Jeddah
United Arab Emirates Administrative office Dubaï
Venezuela Administrative office Caracas

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

Algeria,  Brazil,  Israel,  Lebanon,  Mexico,  Morocco,  Peru,  Saudi Arabia,  United Arab Emirates,  Venezuela, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c level for patients with addition of glulisine at week 12 between week 12 and week 24 (end of treatment period) No
Secondary Percentage of patients with HbA1c level < 7% at week 24 (end of treatment period) No
Secondary Percentage of patients with HbA1c level < 7% and no symptomatic nocturnal hypoglycemia event at week 24 (end of treatment period) No
Secondary Fasting Plasma Glucose at week 0, week 12 and week 24 No
Secondary 7-point Self Monitoring of Blood Glucose at week 0, week 12 and week 24 No
Secondary Daily dose of insulin glargine at week 24 (end of treatment period) No
Secondary Daily dose of insulin glulisine at week 24 (end of treatment period) No
Secondary Systolic / diastolic blood pressure, heart rate, weight change from week 0 (baseline) to week 24 (end of treatment period) No
Secondary Hypoglycemia (asymptomatic, symptomatic, nocturnal symptomatic, severe and nocturnal severe) from week 0 (from baseline) to week 24 (end of treatment) Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2